Clinical Trial Evaluate the Cough-relieving and Expectorant Effects of the Health Supplement AZKA Nasal and Throat for Children in Outpatient-treated Pharyngitis
Clinical Trial Evaluate the Cough-relieving and Expectorant Effects of the Health Supplement AZKA Nasal and Throat for Children in Outpatient-treated Pharyngitis
NCT ID: NCT06761339 Phase: NA Status: COMPLETED Enrollment: 24 Completion: 2025-04-28
Conditions
Cough Severity, Cough Frequency, Cough Duration, Phlegm Accumulation (Nasal and Throat Mucus)
Interventions
Azka Nasal and Throat for Children, Prospan cough Syrup
Summary
This is a randomized, open-label, single-center clinical trial evaluating the efficacy and safety of Azka Nasal and Throat for Children compared to the control drug Prospan Cough Syrup in children aged 4-6 years diagnosed with acute nasopharyngitis. Participants will be randomly assigned in a 1:1 ratio to receive either Azka Nasal and Throat or Prospan Cough Syrup for 7 days. The study aims to assess improvements in cough and phlegm conditions, as well as monitor adverse events associated with the interventions. Data will be collected over a 15-day period, including screening, treatment, and follow-up phases.
Primary Outcome
Cough Condition Improvement Assessment